Information on Prioritisations

OIA response

Thank you for your request dated 20 December 2023 under the Official Information Act 1982 (OIA) for information relating to prioritisation. You requested:

  1. A list of medicines and indications reviewed at each of Pharmac’s quarterly ranking meetings between 1 Jan 2020 to 31 Dec 2023.
  2. Have any medicines been ranked out of session during this time?
  3. A list of medicines and indications with a positive recommendation for funding from any Pharmac advisory committee that have yet to be ranked.

You will find the information you requested in your first and second question in the document attached.

We have separated our response by prioritisation meeting, so proposals are grouped with others ranked at each separate meeting. The rankings are separated out into new applications ranked on the Options for Investment (OFI) list, applications re-ranked, applications ranked outside of the meeting, and applications ranked on either the Recommended for Decline(external link) or Only if Cost Neutral/Cost Saving(external link) lists. Note that we did not report proposals which include multiple products for different indications or other proposals which are commercially sensitive. This is allowed under the following OIA grounds:

  • section 9(2)(b)(ii), to protect the commercial position of the person who supplied the information, or who is the subject of the information
  • section 9(2)(ba)(i), to protect the supply of similar information in the future

We have decided to decline your third request under section 18(d) as this information is publicly available and can be accessed via the Application Tracker(external link).

We trust that this information answers your queries. Please note, you have the right to make a complaint to the Ombudsman about our response to your OIA, under section 28(3) of the OIA. Details of how to make a complaint(external link) are on the Ombudsman’s website.

To make information more freely available, we publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.